Wechselwirkungen · Eurartesim
Eurartesim 320 mg/40 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 21–22
HOS-123067 · Präparat HOS-095623
Effect of Eurartesim on co-administered medicinal products Piperaquine is metabolised by, and is an inhibitor of CYP3A4. The concurrent administration of oral Eurartesim with 7.5 mg oral midazolam, a CYP3A4 probe substrate, led to a modest increase (≤2-fold) in midazolam and its metabolites exposures in healthy adult subjects. This inhibitory effect was no longer evident one week after last administration of Eurartesim. Therefore, particular attention should be paid when medicinal products that have a narrow therapeutic index (e.g. antiretroviral medicinal products and cyclosporine) are co-administered with Eurartesim. 21 From in vitro data, piperaquine undergoes a low level of metabolism by CYP2C19, and is also an inhibitor of this enzyme. There is the potential for reducing the rate of metabolism of other substrates of this enzyme, such as omeprazole, with consequent increase of their plasma concentration, and therefore, of their toxicity.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cyclosporine (HOS-084512) midazolam (HOS-086167) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-04T13:58:00Z · SHA-256 dabfe6fde6102b83217e8e60df06f7976dca1a5f1a6c99e5db65545ad780075f · Passage 19f51d49a89adae56e3b0d1fc58539c9d08e862195f64a67d3e9af32b05f8108 · Zeichen 508–1515 im Abschnitt